Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

A US court has upheld AstraZeneca’s patents on its respiratory drug Symbicort, blocking cheaper ... with a fast action, in a single inhaler. A Viatris spokesperson said: "Viatris obviously ...

Pulmonary Or Respiratory Drug Delivery Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research ...

Alongside Fasenra and Symbicort, Tezspire became the third blockbuster ... Starting with Breztri, our triple combination inhaler, already approved in COPD. We have the opportunity to improve ...

in a single inhaler, the Ellipta. Sales of the drug are starting to pick up since its slow start in 2013, and in Q1 the drug recorded revenues of £204million ($264m), up 84% on the same period ...

AZN earnings call for the period ending December 31, 2024.

Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). · In July 2023, Drug ...

A young Wisconsin man died from an asthma attack after the price of his inhaler skyrocketed nearly $500, according to a lawsuit filed by his family.

DUBLIN--(BUSINESS WIRE)--The "Inhalation and Nasal Spray Generic Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Inhalation and ...

ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

The rising prevalence of respiratory diseases and technological advancements drive significant market growth.Pune, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Aerosol Drug Delivery Devices Market Size & Growth ...